Clinical Characteristics and Prognosis in South-American Patients with Myelodysplastic Syndrome: A Multicenter Study

BELLI C; FEITOSA PINHEIRO R; FLORES G; MAGALHAES S; KORNBLIHTT L; ENRICO A; CORDEIRO J; BASQUEIRA AL; CAVALCANTE M; PINTOS N; ALFONSO G; ARBELBIDE J; SAKAMOTO F; WATMAN N; LARRIPA I; UNDURRAGA S; VELLOSO E

San Francisco

Congreso; 56th ASH Annual Meeting and Exposition; 2014

American Society of Hematology

There are previous reported data describing differences between European and Asian patients with Myelodysplastic Syndromes (MDS), and little is known about South-American (SA) patients. Our aim was to describe clinical characteristic of SA MDS population, to compare our series with diverse ethnicity, to evaluate scoring systems and prognostic factors. We retrospectively analysed a series of 1080 patients with de novo MDS (1981-2014) from Argentine (Ar-635), Brazil (Br-345), and Chile (Ch-100). Patients were classified following FAB and WHO criteria, excluding patients with bone marrow (BM) blasts >30% and CMML with white blood cells count >12x109/L. Patients undergoing hematopoietic stem cell transplantation (5%) or hypomethylating therapy (12%) were censored at treatment initiation. Chilean patients were younger (mean age: 59 vs 66-Ar, p